Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line

Published:2017-01-01 Issue:1 Volume:14 Page:83-92
ISSN:1790-6245
Container-title:Cancer Genomics & Proteomics
language:
Short-container-title:CGP

Author:

MIYATA HARUO,ASHIZAWA TADASHI,IIZUKA AKIRA,KONDOU RYOTA,NONOMURA CHIZU,SUGINO TAKASHI,URAKAMI KENICHI,ASAI AKIRA,HAYASHI NAKAMASA,MITSUYA KOICHI,NAKASU YOKO,YAMAGUCHI KEN,AKIYAMA YASUTO

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Genetics,Molecular Biology,Biochemistry

Link

http://cgp.iiarjournals.org/content/14/1/83.full.pdf

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of calcium-binding protein S100P on temozolomide sensitivity in glioblastoma cells;Gene Reports;2024-03

2. The Role of Chitinase-3-like Protein-1 (YKL40) in the Therapy of Cancer and Other Chronic-Inflammation-Related Diseases;Pharmaceuticals;2024-02-27

3. Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer;Pharmaceuticals;2023-07-14

4. Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O-6-Methylguanine-DNA Methyltransferase;CNS & Neurological Disorders - Drug Targets;2023-07

5. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches;Current Molecular Medicine;2023-05-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP